CO2023008958A2 - Acopladores de células asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123 - Google Patents

Acopladores de células asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123

Info

Publication number
CO2023008958A2
CO2023008958A2 CONC2023/0008958A CO2023008958A CO2023008958A2 CO 2023008958 A2 CO2023008958 A2 CO 2023008958A2 CO 2023008958 A CO2023008958 A CO 2023008958A CO 2023008958 A2 CO2023008958 A2 CO 2023008958A2
Authority
CO
Colombia
Prior art keywords
natural killer
human
nkp46
multifunctional natural
abd
Prior art date
Application number
CONC2023/0008958A
Other languages
English (en)
Inventor
Angela Virone-Oddos
Francis Duffieux
Laurent Gauthier
Ariane Thielens
Benjamin Rossi
Céline Amara
Céline Nicolazzi
Marielle Chiron
Jochen Beninga
Original Assignee
Sanofi Sa
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Innate Pharma filed Critical Sanofi Sa
Publication of CO2023008958A2 publication Critical patent/CO2023008958A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere a proteínas de unión multifuncionales que comprenden un primer y un segundo dominios de unión a antígeno (ABD) y toda o parte de una región Fc de inmunoglobulina o variante de la misma, en donde el primer ABD se une específicamente a CD123 humano y el segundo ABD se une específicamente a NKp46 humano y en donde toda o parte de la región Fc de inmunoglobulina o variante de la misma se unen a un receptor de Fc-γ humano. La divulgación también se refiere a métodos para preparar dichas proteínas de unión, composiciones de las mismas y sus usos, incluido el tratamiento o la prevención de trastornos proliferativos, incluida Leucemia Mieloide Aguda (AML) y síndromes mielodisplásicos (MDS).
CONC2023/0008958A 2020-12-31 2023-07-05 Acopladores de células asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123 CO2023008958A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306717 2020-12-31
US202163256950P 2021-10-18 2021-10-18
PCT/IB2021/062494 WO2022144836A1 (en) 2020-12-31 2021-12-30 Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123

Publications (1)

Publication Number Publication Date
CO2023008958A2 true CO2023008958A2 (es) 2023-08-18

Family

ID=79316794

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0008958A CO2023008958A2 (es) 2020-12-31 2023-07-05 Acopladores de células asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123

Country Status (11)

Country Link
US (2) US11692039B2 (es)
EP (1) EP4271709A1 (es)
JP (1) JP2024501539A (es)
KR (1) KR20230127306A (es)
AU (1) AU2021414400A1 (es)
CA (1) CA3206883A1 (es)
CO (1) CO2023008958A2 (es)
IL (1) IL304124A (es)
MX (1) MX2023007901A (es)
TW (1) TW202241952A (es)
WO (1) WO2022144836A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6840682B2 (ja) * 2015-06-23 2021-03-10 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的抗原結合タンパク質

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
ATE447613T1 (de) 1997-11-17 2009-11-15 Micromet Ag Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten
EP1161453A4 (en) 1999-02-08 2005-01-05 Medvet Science Pty Ltd CYTOKIN-BINDING DOMAIN
AU773029B2 (en) 1999-02-08 2004-05-13 Medvet Science Pty. Ltd. Cytokine-binding domain
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
EP1263463B1 (en) 2000-03-06 2011-05-25 University of Kentucky Research Foundation Use of an antibody or an immunotoxin that selectively binds to cd123 to impair hematologic cancer progenitor cells
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
JP5010281B2 (ja) 2003-05-31 2012-08-29 マイクロメット アクツィエン ゲゼルシャフト Ｅｐｃａｍに対する二重特異性抗体を含む薬学的組成物
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
EA201070687A1 (ru) 2007-12-06 2010-12-30 Си Эс Эл ЛИМИТЕД Способ ингибирования лейкозных стволовых клеток
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
CA2764432C (en) 2009-04-27 2017-10-24 Kyowa Hakko Kirin Co., Ltd. Interleukin-3 receptor alpha chain-binding antibody to treat leukemia
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
KR101842907B1 (ko) 2010-02-17 2018-03-28 씨에스엘 리미티드 제 ⅰ형 인터페론을 생산하는 세포를 표적화하기 위한 조성물 및 방법
BR112012031189B1 (pt) 2010-06-07 2021-10-26 Stepan Company Composição, composição biocida diluível e método de limpeza de uma superfície dura
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
JPWO2012046772A1 (ja) 2010-10-06 2014-02-24 国立大学法人 東京大学 リンパ浮腫予防治療剤
WO2012059858A1 (en) 2010-11-01 2012-05-10 Symphogen A/S Anti-her3 antibodies and compositions
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
WO2012089814A1 (en) 2010-12-30 2012-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
CN103492562B (zh) * 2011-02-03 2017-04-05 佐马技术有限公司 用于增强细菌中功能蛋白表达的方法和材料
WO2014138805A1 (en) 2013-03-14 2014-09-18 Csl Limited Anti il-3r alpha agents and uses thereof
US20160046718A1 (en) 2013-03-14 2016-02-18 Csl Limited Agents that neutralize il-3 signalling and uses thereof
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
PL3119807T3 (pl) 2014-03-19 2019-09-30 Cellectis Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów
NZ726513A (en) 2014-05-28 2023-07-28 Memorial Sloan Kettering Cancer Center Anti-gitr antibodies and methods of use thereof
US20180134795A1 (en) 2014-06-17 2018-05-17 Cellectis Cd123 specific multi-chain chimeric antigen receptor
JP6702893B2 (ja) 2014-06-27 2020-06-03 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的抗原結合タンパク質
CA2952727A1 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific nkp46 binding proteins
CN105367657B (zh) 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
RS60305B1 (sr) 2014-09-05 2020-07-31 Janssen Pharmaceutica Nv Agensi koji vezuju cd123 i njihove upotrebe
EP4183806A3 (en) 2014-11-12 2023-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP4039710A3 (en) 2015-01-23 2022-10-19 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
BR112017015453A2 (pt) 2015-01-26 2018-01-23 Cellectis células imunes modificadas knockout para receptor de células t, dotadas de receptores quiméricos de antígeno, de ligação a cd123 para o tratamento de linfoma mieloide agudo recorrente/refratário ou neoplasia blástica de células dendríticas plasmacitoides
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
US10744205B2 (en) 2015-06-23 2020-08-18 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies
US10113003B2 (en) 2015-06-23 2018-10-30 Innate Pharma Multispecific NK engager proteins
JP6840682B2 (ja) 2015-06-23 2021-03-10 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的抗原結合タンパク質
JP2018522907A (ja) 2015-08-11 2018-08-16 セレクティスＣｅｌｌｅｃｔｉｓ Ｃｄ３８抗原を標的とするためおよびｃｄ３８遺伝子を不活化するために操作された、免疫療法用の細胞
IL302822A (en) 2015-11-12 2023-07-01 Seagen Inc Compounds interacting with glycans and methods of use
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
CA3007022A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
EP3383914A4 (en) 2015-12-02 2019-10-30 Agenus Inc. ANTI-OX40 ANTIBODIES AND METHODS OF USE
JP7091250B2 (ja) 2015-12-28 2022-06-27 イナート・ファルマ・ソシエテ・アノニム ＮＫｐ４６結合タンパク質の可変領域
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
EP3469001A4 (en) 2016-06-09 2020-05-06 Seattle Genetics, Inc. COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS
AU2018371114A1 (en) 2017-11-21 2020-05-07 Innate Pharma Multispecific antigen binding proteins
BR112021016791A2 (pt) 2019-02-26 2021-11-16 Sorrento Therapeutics Inc Proteínas de ligação de antígenos que se ligam a bcma
WO2022200525A1 (en) 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
EP4352098A1 (en) 2021-06-09 2024-04-17 Innate Pharma Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a

Also Published As

Publication number Publication date
AU2021414400A1 (en) 2023-08-17
JP2024501539A (ja) 2024-01-12
KR20230127306A (ko) 2023-08-31
MX2023007901A (es) 2023-07-11
IL304124A (en) 2023-09-01
TW202241952A (zh) 2022-11-01
CA3206883A1 (en) 2022-07-07
US20230416383A1 (en) 2023-12-28
US20220213202A1 (en) 2022-07-07
WO2022144836A1 (en) 2022-07-07
EP4271709A1 (en) 2023-11-08
US11692039B2 (en) 2023-07-04

Similar Documents

Publication Publication Date Title
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
PH12020550408A1 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
JP2018517431A5 (es)
JP2017504578A5 (es)
PE20220278A1 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
CO2023008958A2 (es) Acopladores de células asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123
PE20181310A1 (es) Anticuerpos anti-il1rap, moleculas de union a antigenos biespecificas que se unen a il1rap y cd3, y usos de estos
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
EA201891066A1 (ru) Антитела к ror1
PH12021550662A1 (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
AR100680A1 (es) Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
EA202190542A1 (ru) Сконструированные биспецифические белки
EA202090718A1 (ru) Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
FI3402821T3 (fi) PSMA-sitova vasta-aine ja sen käyttöjä
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
EA202092460A1 (ru) Антитела к ox40 и способы применения
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
EP4249097A3 (en) Fc binding proteins with cysteine in the c-terminal helical region
MX2020010094A (es) Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
EA201691782A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
EA202191231A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ
RU2019129174A (ru) Белки, связывающие cd33, nkg2d и cd16
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
CR20210628A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos